These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30062709)

  • 1. The effects of quercetin supplementation on metabolic and hormonal parameters as well as plasma concentration and gene expression of resistin in overweight or obese women with polycystic ovary syndrome.
    Khorshidi M; Moini A; Alipoor E; Rezvan N; Gorgani-Firuzjaee S; Yaseri M; Hosseinzadeh-Attar MJ
    Phytother Res; 2018 Nov; 32(11):2282-2289. PubMed ID: 30062709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
    Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
    Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Quercetin on Adiponectin-Mediated Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Double-Blind Clinical Trial.
    Rezvan N; Moini A; Janani L; Mohammad K; Saedisomeolia A; Nourbakhsh M; Gorgani-Firuzjaee S; Mazaherioun M; Hosseinzadeh-Attar MJ
    Horm Metab Res; 2017 Feb; 49(2):115-121. PubMed ID: 27824398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome.
    Asemi Z; Foroozanfard F; Hashemi T; Bahmani F; Jamilian M; Esmaillzadeh A
    Clin Nutr; 2015 Aug; 34(4):586-92. PubMed ID: 25300649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome.
    Arikan S; Bahceci M; Tuzcu A; Kale E; Gökalp D
    Gynecol Endocrinol; 2010 Mar; 26(3):161-6. PubMed ID: 20148738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome.
    Yang HY; Ma Y; Lu XH; Liang XH; Suo YJ; Huang ZX; Lu DC; Qin YF; Luo ZJ
    Ann Endocrinol (Paris); 2015 Oct; 76(5):620-7. PubMed ID: 26514948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women.
    Sanke S; Chander R; Jain A; Garg T; Yadav P
    JAMA Dermatol; 2016 Sep; 152(9):986-91. PubMed ID: 27304785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage migration inhibitory factor in obese and non obese women with polycystic ovary syndrome.
    Mejia-Montilla J; Álvarez-Mon M; Reyna-Villasmil E; Torres-Cepeda D; Santos-Bolívar J; Reyna-Villasmil N; Suarez-Torres I; Bravo-Henríquez A
    Endocrinol Nutr; 2015 Jan; 62(1):31-7. PubMed ID: 25458401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating apelin level in relation to nutritional status in polycystic ovary syndrome and its association with metabolic and hormonal disturbances.
    Olszanecka-Glinianowicz M; Madej P; Nylec M; Owczarek A; Szanecki W; Skałba P; Chudek J
    Clin Endocrinol (Oxf); 2013 Aug; 79(2):238-42. PubMed ID: 23199261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Oligopin Supplementation on Hormonal and Metabolic Profiles in the Polycystic Ovary Syndrome: A Randomized Controlled Trial.
    Qorbani M; Sanginabadi M; Mohajeri-Tehrani MR; Karimi S; Gerami H; Mahdavi-Gorabi A; Shirzad N; Samadi M; Baygi F; Hosseini S; Mansour A
    Front Endocrinol (Lausanne); 2020; 11():590392. PubMed ID: 33408691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of L-carnitine supplementation on insulin resistance, sex hormone-binding globulin and lipid profile in overweight/obese women with polycystic ovary syndrome: a randomized clinical trial.
    Sangouni AA; Pakravanfar F; Ghadiri-Anari A; Nadjarzadeh A; Fallahzadeh H; Hosseinzadeh M
    Eur J Nutr; 2022 Apr; 61(3):1199-1207. PubMed ID: 34727201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in overweight and obese women with polycystic ovary syndrome: a randomized controlled intervention study.
    Mehrabani HH; Salehpour S; Amiri Z; Farahani SJ; Meyer BJ; Tahbaz F
    J Am Coll Nutr; 2012 Apr; 31(2):117-25. PubMed ID: 22855917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
    Singh S; Akhtar N; Ahmad J
    Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
    Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
    Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.